Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome

Introduction: Positron emission tomography/computer tomography (PET/CT) targeting the prostate-specific membrane antigen (PSMA) is crucial for the assessment of adequate PSMA expression in patients with metastatic castration-resistant prostate cancer (mCRPC) prior to PSMA radioligand therapy (PSMA R...

Full description

Bibliographic Details
Main Authors: Philipp E. Hartrampf, Constantin Lapa, Sebastian E. Serfling, Andreas K. Buck, Anna Katharina Seitz, Philipp T. Meyer, Juri Ruf, Kerstin Michalski
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
PSMA
FDG
PET/CT
prostate cancer
radioligand therapy
Online Access:https://www.mdpi.com/2072-6694/13/17/4270

Internet

https://www.mdpi.com/2072-6694/13/17/4270

Similar Items